![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis Announces New Supervisory Board of Curetis N.V.
October 29, 2015 09:30 ET
|
Curetis AG
AMSTERDAM, The Netherlands and HOLZGERLINGEN, Germany, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Curetis B.V.1 ("Curetis"), a developer of next-level molecular diagnostic solutions, today announced the...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis and Acumen to Collaborate on Unyvero Sepsis Test and ASEAN Distribution
October 05, 2015 11:00 ET
|
Curetis AG
Curetis licenses Acumen's proprietary sepsis biomarker panel for use with Unyvero Platform
Diagnostics Development (DxD) Hub in Singapore to support Acumen in development and clinical...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis Enters Into Distribution Agreement to Expand Commercial Activities Into Greater China
September 25, 2015 09:30 ET
|
Curetis AG
Exclusive Unyvero distribution agreement with Beijing Clear Biotech Co., Ltd. for Mainland China, Hong Kong and Taiwan
Clinical trials for CFDA regulatory approval in...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis Initiates Next Phase of Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections
July 08, 2015 10:39 ET
|
Curetis AG
First patient enrolled in prospective arm of IVD trial
Study to include a total of at least 2,500 patient samples
Milestone triggers payment of EUR 6.8 million financing...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis' Unyvero System Selected for Global Phase III Antibiotics Trial
June 24, 2015 09:56 ET
|
Curetis AG
HOLZGERLINGEN, Germany, June 24, 2015 (GLOBE NEWSWIRE) -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Curetis' Unyvero System will be used in a Phase III...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis Strengthens Executive Team; Appoints Dr. Achim Plum as Chief Commercial Officer
May 11, 2015 09:30 ET
|
Curetis AG
HOLZGERLINGEN, Germany, May 11, 2015 (GLOBE NEWSWIRE) -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced Dr. Achim Plum has been appointed to the newly-created...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis Expands Commercial Organization
April 20, 2015 09:30 ET
|
Curetis AG
Augmented direct sales force, led by new Head of International Sales, to broaden reach in key European markets
New distribution partnerships in Italy and Middle East
HOLZGERLINGEN, Germany,...
![Curetis AG logo](/news-release/logo/337598/0/337598.jpg?lastModified=12%2F09%2F2016%2023%3A13%3A39&size=2)
Curetis to Launch Next-Generation Pneumonia Application at ECCMID 2015
April 16, 2015 09:30 ET
|
Curetis AG
- Company Successfully Completes Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application
- Clinical sensitivity across 40-marker panel averages 94% at 99.4% specificity...